Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 2						Print
																Related Pages
										On This Page
			OverviewIntroductionMethodsResultsGRADE Summary
		
Overview
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infection (LRTI) in children <24 months who are at increased risk of severe disease entering their second RSV season was presented to the Advisory Committee on Immunization Practices (ACIP) on February 23, 2023. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from high certainty to very low certainty [*1*].
The policy question was, “Should one dose of nirsevimab be recommended for children aged 8–19 months* who are at increased risk of severe RSV disease and entering their second RSV season† (200 mg) ?” The benefits chosen by ACIP Maternal/Pediatric RSV Work Group (Work Group) as critical or important to policy decisions were prevention of medically attended RSV-associated LRTI (critical); RSV-associated LRTI with hospitalization (critical); RSV-associated LRTI with intensive care unit (ICU) admission (critical); RSV-associated death (critical); all-cause medically attended LRTI (important); and all-cause LRTI-associated hospitalization (important). The harm chosen by the Work Group as important to policy decisions was serious adverse events (SAEs) (important). The quality of evidence from one Phase 2/3 randomized controlled trial (RCT) with standard of care as the comparator (palivizumab) was assessed using the GRADE approach [*2-4*].
Benefit outcomes for GRADE were assessed up to 150 days after injection. No direct efficacy data was available. Thus, pharmacokinetic extrapolation was used and based on comparable pharmacokinetic levels from efficacy in infants <12 months of age for prevention of the first medically attended RSV-associated LRTI to pharmacokinetic levels in children ≤24 months with chronic lung disease (CLD) or congenital heart disease (CHD) entering their second RSV season (evidence certainty: low). No data was available for other benefits.
The evidence indicated that SAEs§ might not be more common in the intervention group than placebo group (RR 8.4; 95% CI: 0.52, 135.5; evidence certainty: very low).Introduction
On July 17, 2023, the U.S. Food and Drug Administration (FDA) approved nirsevimab (Beyfortus, commercialized by Sanofi, manufactured by AstraZeneca), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in infants and young children [*5*]. As part of the process employed by ACIP, a systematic review and GRADE evaluation of the evidence for nirsevimab was conducted and presented to ACIP. ACIP adopted a modified GRADE approach in 2010 as the framework for evaluating the scientific evidence that informs recommendations for the use of vaccines, immune globulin preparations, and specific antibody products [6]. Evidence of benefits and harms were reviewed based on the GRADE approach [*1*]. No conflicts of interest were reported by CDC and Work Group members involved in the GRADE analysis.
The policy question was, “Should one dose of nirsevimab be recommended for children who are at increased risk of severe RSV disease entering their second RSV season and 8–19 months of age at time of immunization?” (Table 1). For information on GRADE related to the first RSV season indication, please see: https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season1-rsv-infants-children.html.Methods
We conducted a systematic review of evidence on the efficacy, pharmacokinetic data, and safety of nirsevimab received by children 8–19 months entering their second RSV season. We assessed outcomes and evaluated the quality of evidence using the GRADE approach from August 2022–February 2023.
Work Group members were asked to pre-specify and rate the importance of relevant patient-important outcomes before the GRADE assessment. Outcomes of interest included individual benefits and harms (Table 2). The critical benefits of interest for infants selected by the Work Group were medically attended RSV-associated LRTI, RSV-associated LRTI with hospitalization, RSV-associated LRTI with ICU admission, and RSV-associated death. Important benefits of interest are all-cause medically attended LRTI and all-cause LRTI-associated hospitalization. The harm outcome rated by the workgroup as important was SAEs.
A systematic literature search was completed to review all available evidence on the efficacy, pharmacokinetics, and safety of nirsevimab. Records of relevant observational studies as well as randomized controlled trials were included if they 1) provided data on infants injected with nirsevimab; 2) involved human subjects; 3) reported primary data; and 4) included data relevant to the efficacy and safety outcomes being measured. We identified relevant studies through Medline, Embase, Cochrane Library, CINAHL, Scopus, and clinicaltrials.gov. No relevant observational studies were identified through the systematic review. The systematic review was conducted through May, 2022. Characteristics of all included studies are shown in Appendix 1 and evidence retrieval methods are found in Appendix 2.
The evidence certainty assessment addressed risk of bias, inconsistency, indirectness, imprecision, and other characteristics. The GRADE assessment across the body of evidence for each outcome was presented in an evidence profile; evidence could be assessed as certainty of high, moderate, low, or very low certainty.
Relative risk (RR) for harm outcomes were calculated using event counts and total persons at risk available from one Phase 2/3 RCT.Results
The results of the GRADE assessment were presented to ACIP on February 23, 2023. Data were reviewed from one published Phase 2/3 RCT, plus additional data provided by the sponsor and FDA [2-4,7].
The Phase 2/3 RCT was not designed or powered to evaluate efficacy. There were no cases of medically attended RSV-associated LRTI in the second RSV season through 150 days post dose, which was conducted in 2020 during the COVID-19 pandemic. In the absence of direct efficacy data for high-risk children entering their second RSV season, two pharmacokinetic data endpoints were used to extrapolate efficacy from the Phase 2b and Phase 3 trials among infants that did not qualify for palivizumab [8,9]: the day 150 nirsevimab serum concentration and an area under the curve nirsevimab concentration. The day 150 post-dose serum concentration of nirsevimab among high-risk children in their second RSV season of the Phase 2/3 trial was higher than the concentrations reported in the Phase 3 trial among late preterm and term infants. More than 90% of the high-risk children in the Phase 2/3 trial had nirsevimab area under the curve concentrations that exceeded the target (Table 3a). FDA considered extrapolation of efficacy data from other trials to be appropriate because the pathophysiology of RSV infection, mechanism of action of nirsevimab, and response to nirsevimab is expected to be sufficiently similar between the populations of the efficacy trials and the pharmacokinetic trial [7].
For evaluation of potential harms, SAEs were not significantly different in the intervention group than the placebo group (RR: 8.4 [95% CI: 0.52, 135.5])¶ (Table 3b). FDA noted in the 150-days post-dose follow-up period for RSV season 2, there were no adverse reactions (adverse events judged as drug-related); the most commonly reported adverse event was pyrexia, which was reported in 13.2% of subjects who received nirsevimab and 11.9% of subjects who received palivizumab [*7*].GRADE Summary
The initial GRADE evidence level was type 1 (high) for each outcome because the body of evidence consisted of randomized controlled trials [*1*]. In terms of critical benefits, pharmacokinetic extrapolation from efficacy in infants <12 months of age for prevention of the first medically attended RSV-associated LRTI to pharmacokinetic levels in children ≤24 months with CLD or CHD entering their second RSV season met pre-determined thresholds. This outcome was downgraded twice for very serious concern for indirectness, due to surrogate outcome, surrogate outcomes was established among infants born during or entering their 1st RSV season while trial data is from children entering their 2nd RSV season, and trial population that does not match proposed indication. This resulted in low certainty in the outcome. For the important harm outcome of SAEs, the available data showed that SAEs might not be more common in intervention group than placebo group with very low certainty. Certainty for the outcome of SAEs was downgraded once for serious concern for indirectness as the comparison group is palivizumab rather than placebo and very serious concern for imprecision due to the width of the confidence interval containing estimates for which different policy decisions might be considered (Table 4). The overall certainty in the evidence was very low.
Footnotes
*  Infants aged ≥8 months of age have likely experienced an RSV season and are at decreased risk of severe RSV-associated disease compared with younger infants without prior RSV exposure. Children at increased risk of severe disease aged ≥20 months of age have likely experienced two RSV seasons.
† Those at increased risk include children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season; children with profound immunocompromise (e.g., children who received a hematopoietic stem cell transplant, with severe combined immunodeficiency); children with cystic fibrosis who either have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or weight-for-length <10th percentile; and American Indian and Alaska Native children.
§ Serious adverse events were defined as death, events that were life-threatening or required inpatient hospitalization, events that prolonged hospitalization, events that were persistent or that were associated with clinically significant disability or incapacity, or events that were considered to be of medical significance.
¶No serious adverse events were recorded in the group that received palivizumab in the first and second RSV season, therefore, the relative risk was calculated using the standard offset of 0.5.
**References**
Ahmed F. U.S. Advisory Committee on Immunization Practices (ACIP) Handbook for Developing Evidence-based Recommendations.
Domachowske JB, Cheng Y, Atanasova V, Cabañas F, Furuno K, Nguyen KA, et al. Safety of re-dosing nirsevimab prior to RSV season 2 in children with heart or lung disease, *Journal of the Pediatric Infectious Diseases Society*, 2023;piad052. doi: 10.1093/jpids/piad052
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. *New England Journal of Medicine.* 2023;386(9): 892–894. doi: 10.1056/NEJMc2112186
Sanofi/AstraZeneca, 2023 personal communication, August 2022 – February 2023.
FDA. Nirsevimab approval press release. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
CDC ACIP charter https://www.cdc.gov/vaccines/acip/committee/charter.html
FDA Briefing Document, Nirsevimab https://www.fda.gov/media/169226/download
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. *New England Journal of Medicine*. 2022; 386(9): 837–846. doi: 10.1056/NEJMoa2110275
Muller WJ, Madhi SA, Seoane Nunez B, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. *New England Journal of Medicine.* 2023; 388(16): 1533–1534. doi: 10.1056/NEJMc2214773Table 1: Policy Questions and PICO
Table 1: Policy Questions and PICO
Policy question
Should one dose of nirsevimab be recommended for children 8–19 months of age with increased risk of severe disease entering their second RSV season?**Population**
Children 8–19 months of age with increased risk of severe disease entering their second RSV seasonIntervention
Nirsevimab (200mg [2x100mg], IM)Comparison
No nirsevimab prophylaxisOutcomes
Medically attended RSV-associated LRTI
RSV-associated LRTI with hospitalization
RSV-associated LRTI with ICU admission
RSV-associated death
All-cause medically attended LRTI
All-cause LRTI-associated hospitalization
Serious adverse events**Abbreviations:** RSV= respiratory syncytial virus; IM= intramuscular; LRTI= lower respiratory tract infection; ICU= intensive care unitTable 2: Outcomes and Rankings
Table 2: Outcomes and Rankings
Outcome
Importance
Included in evidence profileMedically attended RSV-associated LRTI
Critical
YesRSV-associated LRTI with hospitalization
Critical
NoRSV-associated LRTI with ICU admission
Critical
NoRSV-associated death
Critical
NoAll-cause medically attended LRTI
Important
NoAll-cause LRTI-associated hospitalization
Important
NoSerious adverse events
Important
Yes**Abbreviations:** RSV= respiratory syncytial virus; LRTI= lower respiratory tract infection; ICU= intensive care unitTable 3a: Summary of studies reporting medically attended RSV-associated LRTIa
Table 3a: Summary of studies reporting medically attended RSV-associated LRTI
Authors last name, pub year
Age or other characteristic of importance
Intervention
Comparison
Comparator
Measure
Study limitations (Risk of Bias)Domachowske, 2022 Phase 2/3 RCTd
Children who were eligible to receive palivizumab as infants with CHD or CLD and are entering their second RSV season.
200-mg of nirsevimab
15 mg per kilogram of body weight per dose of palivizumab
Placebo
Pharmacokinetic extrapolation from efficacy data in infants born during or entering their first RSV season for prevention of medically attended RSV-associated LRTI to pharmacokinetic levels in children ≤24 months with CLD or CHD entering their second RSV seasonb
None
**Abbreviations:** RCT= randomized control trial; RSV= respiratory syncytial virus; LRTI= lower respiratory tract infection; CLD= chronic lung disease; CHD= congenital heart diseasea Medically attended RSV-associated LRTI was defined as ≥1 documented physical examination findings localizing to the lower respiratory tract: rhonchi; rales; crackles; or wheeze and ≥1 clinical sign of severity: increased respiratory rate (age <2 months, ≥60 breaths/min; age 2–6 months, ≥50 breaths/min; age >6 months to 2 years, ≥40 breaths/min); hypoxemia in room air-oxygen saturation <95% at altitudes ≤1,800 meters or <92% at altitudes >1,800 meters; acute hypoxic or ventilatory failure; new onset apnea; nasal flaring; retractions (intercostal, subcostal, or supraventricular retractions); grunting; dehydration due to respiratory distress with an inpatient or outpatient encounter and RSV PCR positive test.b Pharmacokinetic extrapolation was used and based on comparable pharmacokinetic levels from efficacy in infants <12 months of age for prevention of the first medically attended RSV LRTI to pharmacokinetic levels in children ≤24 months with chronic lung disease (CLD) or congenital heart disease (CHD) entering their second RSV season. Based on pharmacokinetic and efficacy data from the Phase 2b and Phase 3 (MELODY) trials, a target area under the curve nirsevimab concentration of >12.8 mg*day/ml was established. For the CLD cohort, 129/132 (98%) participants met the target nirsevimab concentration, and for the CHD cohort, 58/58 (92%) participants met the target. Additionally, the concentration of nirsevimab 150 days after injection was higher compared with the 150-day concentration in the Phase 3 trial nirsevimab arm population.Table 3b: Summary of studies reporting serious adverse eventsa
Table 3b: Summary of studies reporting serious adverse events
Authors last name, pub year
Age or other characteristic of importance
n/N (%) interventionb
n/N (%) comparisonc
Comparator
RR (95% CI)d
Study limitations (Risk of Bias)Domachowske, 2022 Phase 2/3 RCT
Children who were eligible to receive palivizumab as infants with CHD or CLD and are entering their second RSV season.
21/220 (9.5)
0/42 (0)
Placebo
8.4 (0.52, 135.5)
None
**Abbreviations:**RR= relative risk; CI= confidence interval; RCT= randomized controlled trial.a Serious adverse events were defined as death, events that were life-threatening or required inpatient hospitalization, events that prolonged hospitalization, events that were persistent or that were associated with clinically significant disability or incapacity, or events that were considered to be of medical significance.bSeason 1: single injection of 50 mg of nirsevimab if the infant weighed <5 kg or 100 mg if they weighed ≥5 kg; season 2: single injection of 200-mg of nirsevimab.c Season 1 and 2:  injection of 15 mg per kilogram of body weight of palivizumab.dNo serious adverse events were recorded in the group that received palivizumab in the first and second RSV season, therefore, the relative risk was calculated using the standard offset of 0.5Table 4: GRADE Evidence Profile Tables
Grade Summary of Findings Table
Certainty assessment
No of patients
Effect
Certainty
ImportanceNo of studies
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
nirsevimab
palivizumab
Relative
(95% CI)
Absolute
(95% CI)Medically attended RSV-associated LRTI1
randomized trial
not serious
not serious
not serious
very seriousa
none
Pharmacokinetic extrapolation was used and based on comparable pharmacokinetic levels from efficacy in infants <12 months of age for prevention of the first medically attended RSV LRTI to pharmacokinetic levels in children ≤24 months with chronic lung disease (CLD) or congenital heart disease (CHD) entering their second RSV seasonb
n/a
n/a
⨁⨁◯◯
Low
CRITICALSerious adverse events1
randomized trial
not serious
not serious
seriousc
very seriousd
none
21/220e
0/42 (0%)
**RR 8.4**
(0.52 to 135.5)f
**86 more per 1,000 (from 6 fewer to 1,000 more)g**
⨁◯◯◯
Very low
Important
**Abbreviations:** CI= confidence interval; RR= risk ratioa Very serious concern for indirectness, due to use of a surrogate outcome, the surrogate was established in infants born during or entering their 1st season while trial data is from children entering their 2nd season, and population that does not match proposed indication.b Pharmacokinetic extrapolation was used and based on comparable pharmacokinetic levels from efficacy in infants <12 months of age for prevention of the first medically attended RSV-associated LRTI to pharmacokinetic levels in children ≤24 months with chronic lung disease (CLD) or congenital heart disease (CHD) entering their second RSV season. Based on pharmacokinetic and efficacy data from the Phase 2b and Phase 3 (MELODY) trials, a target area under the curve nirsevimab concentration of > 12.8 mg*day/ml was established. For the CLD cohort, 129/132 (98%) participants met the target nirsevimab concentration, and for the CHD cohort, 58/58 (92%) participants met the target. Additionally, the concentration of nirsevimab 150 days after injection was higher compared with the 150-day concentration in the Phase 3 trial nirsevimab arm population.c Serious concern for indirectness as the comparison group is palivizumab rather than placebo.d Very serious concern for imprecision due to the width of the confidence interval containing estimates for which different policy decisions might be considered.e 180 trial participants received nirsevimab in both the first and second season. 40 received palivizumab in the first season and nirsevimab in the second seasonf No serious adverse events were recorded in the group that received palivizumab in the first and second RSV season, therefore, the relative risk and 95% confidence interval was calculated using the standard offset of 0.5g No serious adverse events were recorded in the group that received palivizumab in the first and second RSV season, therefore, the absolute risk and 95% confidence interval was calculated using the standard offset of 0.5Appendix 1. Studies Included in the Review of Evidence
Appendix 1. Studies Included in the Review of Evidence
Last name first author, Publication year
Study design
Country (or more detail, if needed)
Population
Age
Total population
N Intervention
N comparison
Outcomes
Funding sourceDomachowske, 2022 and 2023a
Phase 2/3 RCT
Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, Finland, France, Germany, Israel, Japan, South Korea, Latvia, Lithuania, Poland, Russia, Spain, Sweden, United Kingdom, United States, South Africa
Age group, n (%)
≤3 months: 91/310 (59.0%)
>3.0 to ≤6.0 months: 126/310 (31.8%)
>6.0 months: 33/310 (9.1%)
262b (RSV Season 2)
220c
42
Medically attended RSV-associated LRTI; Serious adverse events
MedImmune/AstraZeneca and Sanofi
**Abbreviations:** RCT= randomized controlled trial; RSV= respiratory syncytial virus; LRTI= lower respiratory tract infectiona Additional data provided by sponsor.b 310 children were randomized 2:1 to received palivizumab in the first RSV season of the trial. At the start of the second RSV season, 262 children were randomized 1:1 to receive palivizumab or nirsevimab.c 180 trial participants received nirsevimab in both the first and second season. 40 received palivizumab in the first season and nirsevimab in the second seasonAppendix 2. Databases and strategies used for systematic reviewa
Appendix 2. Databases and strategies used for systematic review
Database
Strategy**Medline****(OVID)****1946-**
Nirsevimab OR MEDI8897 OR ((Antibodies, Monoclonal, Humanized/ OR Antibodies, Monoclonal/) AND (respiratory syncytial virus infections/ OR respiratory syncytial virus, human/)) OR (VRN8S9CW5V OR nirsevimab OR 1989556-22-0).rn OR Nirsevimab.nm
Limit 2015 –**Embase****(OVID)****1974-**
Nirsevimab OR MEDI8897 OR (Monoclonal antibody/ AND human respiratory syncytial virus/) OR (VRN8S9CW5V OR nirsevimab OR 1989556-22-0).rn OR (VRN8S9CW5V OR nirsevimab OR 1989556-22-0).dy
Limit 2015 –**Cochrane Library**
(Nirsevimab OR MEDI8897 OR VRN8S9CW5V OR 1989556-22-0)
Limit 2015 –**CINAHL
(EbscoHost)**
(Nirsevimab OR MEDI8897 OR VRN8S9CW5V OR 1989556-22-0)
Limit 2015 –**Scopus**
TITLE-ABS-KEY(Nirsevimab OR MEDI8897 OR VRN8S9CW5V OR 1989556-22-0)**Clinicaltrials.gov**
(Nirsevimab OR MEDI8897 OR VRN8S9CW5V OR 1989556-22-0)
a Most recent search conducted May 11, 2022.Top of Page
							
					
							Last Reviewed:  August 24, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue